433 related articles for article (PubMed ID: 30905283)
1. Variability in the durability of CRISPR-Cas immunity.
Chabas H; Nicot A; Meaden S; Westra ER; Tremblay DM; Pradier L; Lion S; Moineau S; Gandon S
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180097. PubMed ID: 30905283
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas immunity leads to a coevolutionary arms race between Streptococcus thermophilus and lytic phage.
Common J; Morley D; Westra ER; van Houte S
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180098. PubMed ID: 30905285
[TBL] [Abstract][Full Text] [Related]
3. Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages.
Hynes AP; Villion M; Moineau S
Nat Commun; 2014 Jul; 5():4399. PubMed ID: 25056268
[TBL] [Abstract][Full Text] [Related]
4. Costs of CRISPR-Cas-mediated resistance in Streptococcus thermophilus.
Vale PF; Lafforgue G; Gatchitch F; Gardan R; Moineau S; Gandon S
Proc Biol Sci; 2015 Aug; 282(1812):20151270. PubMed ID: 26224708
[TBL] [Abstract][Full Text] [Related]
5. The population and evolutionary dynamics of phage and bacteria with CRISPR-mediated immunity.
Levin BR; Moineau S; Bushman M; Barrangou R
PLoS Genet; 2013; 9(3):e1003312. PubMed ID: 23516369
[TBL] [Abstract][Full Text] [Related]
6. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
Maniv I; Jiang W; Bikard D; Marraffini LA
J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
[TBL] [Abstract][Full Text] [Related]
7. Why put up with immunity when there is resistance: an excursion into the population and evolutionary dynamics of restriction-modification and CRISPR-Cas.
Gurney J; Pleška M; Levin BR
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180096. PubMed ID: 30905282
[TBL] [Abstract][Full Text] [Related]
8. Cost and benefits of clustered regularly interspaced short palindromic repeats spacer acquisition.
Bradde S; Mora T; Walczak AM
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180095. PubMed ID: 30905281
[TBL] [Abstract][Full Text] [Related]
9. Detecting natural adaptation of the Streptococcus thermophilus CRISPR-Cas systems in research and classroom settings.
Hynes AP; Lemay ML; Trudel L; Deveau H; Frenette M; Tremblay DM; Moineau S
Nat Protoc; 2017 Mar; 12(3):547-565. PubMed ID: 28207002
[TBL] [Abstract][Full Text] [Related]
10. The Biology of CRISPR-Cas: Backward and Forward.
Hille F; Richter H; Wong SP; Bratovič M; Ressel S; Charpentier E
Cell; 2018 Mar; 172(6):1239-1259. PubMed ID: 29522745
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance.
Dupuis MÈ; Villion M; Magadán AH; Moineau S
Nat Commun; 2013; 4():2087. PubMed ID: 23820428
[TBL] [Abstract][Full Text] [Related]
12. CRISPR immunity drives rapid phage genome evolution in Streptococcus thermophilus.
Paez-Espino D; Sharon I; Morovic W; Stahl B; Thomas BC; Barrangou R; Banfield JF
mBio; 2015 Apr; 6(2):. PubMed ID: 25900652
[TBL] [Abstract][Full Text] [Related]
13. The ecology and evolution of microbial CRISPR-Cas adaptive immune systems.
Westra ER; van Houte S; Gandon S; Whitaker R
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20190101. PubMed ID: 30905294
[No Abstract] [Full Text] [Related]
14. Genomic impact of CRISPR immunization against bacteriophages.
Barrangou R; Coûté-Monvoisin AC; Stahl B; Chavichvily I; Damange F; Romero DA; Boyaval P; Fremaux C; Horvath P
Biochem Soc Trans; 2013 Dec; 41(6):1383-91. PubMed ID: 24256225
[TBL] [Abstract][Full Text] [Related]
15. Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems.
Liu Y; Dai L; Dong J; Chen C; Zhu J; Rao VB; Tao P
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938767
[TBL] [Abstract][Full Text] [Related]
16. The effect of bacterial mutation rate on the evolution of CRISPR-Cas adaptive immunity.
Chevallereau A; Meaden S; van Houte S; Westra ER; Rollie C
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180094. PubMed ID: 30905293
[TBL] [Abstract][Full Text] [Related]
17. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
18. Different genetic and morphological outcomes for phages targeted by single or multiple CRISPR-Cas spacers.
Watson BNJ; Easingwood RA; Tong B; Wolf M; Salmond GPC; Staals RHJ; Bostina M; Fineran PC
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180090. PubMed ID: 30905290
[TBL] [Abstract][Full Text] [Related]
19. Host diversity limits the evolution of parasite local adaptation.
Morley D; Broniewski JM; Westra ER; Buckling A; van Houte S
Mol Ecol; 2017 Apr; 26(7):1756-1763. PubMed ID: 27862566
[TBL] [Abstract][Full Text] [Related]
20. Exploitation of the Cooperative Behaviors of Anti-CRISPR Phages.
Chevallereau A; Meaden S; Fradet O; Landsberger M; Maestri A; Biswas A; Gandon S; van Houte S; Westra ER
Cell Host Microbe; 2020 Feb; 27(2):189-198.e6. PubMed ID: 31901522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
